Targeting Chromosomal Instability and Tumour Heterogeneity in HER2-Positive Breast Cancer

被引:44
|
作者
Burrell, Rebecca A. [1 ]
Juul, Nicolai [2 ]
Johnston, Stephen R. [3 ]
Reis-Filho, Jorge S. [4 ]
Szallasi, Zoltan [2 ,5 ]
Swanton, Charles [1 ,3 ]
机构
[1] London Res Inst, Translat Canc Therapeut Lab, London WC2A 3PX, England
[2] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark
[3] Royal Marsden Hosp, Breast Unit, Dept Med, Sutton SM2 5PT, Surrey, England
[4] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[5] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol CHIP HST, Childrens Hosp Informat Program, Boston, MA 02115 USA
关键词
CHROMOSOMAL INSTABILITY; HER2; BREAST CANCER; DRUG RESISTANCE; TUMOUR HETEROGENEITY; MICROTUBULE; CEP17; SPINDLE ASSEMBLY CHECKPOINT; TAXOL-INDUCED APOPTOSIS; IN-SITU HYBRIDIZATION; PHASE-II TRIAL; MITOTIC CHECKPOINT; 1ST-LINE TREATMENT; INTRATUMORAL HETEROGENEITY; RETROSPECTIVE ANALYSIS; KARYOTYPIC COMPLEXITY; ADJUVANT CHEMOTHERAPY;
D O I
10.1002/jcb.22781
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chromosomal instability (CIN) is a common cause of tumour heterogeneity and poor prognosis in solid tumours and describes cell-cell variation in chromosome structure or number across a tumour population. In this article we consider evidence suggesting that CIN may be targeted and may influence response to distinct chemotherapy regimens, using HER2-positive breast cancer as an example. Pre-clinical models have indicated a role for HER2 signalling in initiating CIN and defective cell-cycle control, and evidence suggests that HER2-targeting may attenuate this process. Anthracyclines and platinum agents may target tumours with distinct patterns of karyotypic complexity, whereas taxanes may have preferential activity in tumours with relative chromosomal stability. A greater understanding of karyotypic complexity and identification of methods to directly examine and target CIN may support novel strategies to improve outcome in cancer. J. Cell. Biochem. 111: 782-790, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:782 / 790
页数:9
相关论文
共 50 条
  • [41] Treatment Combinations for HER2-Positive Breast Cancer
    Pegram, Mark
    ONCOLOGY-NEW YORK, 2013, 27 (04): : 258 - +
  • [42] Management of HER2-Positive Early Breast Cancer
    Steger, Guenther
    Lueftner, Diana
    Stoeger, Herbert
    Thurlimann, Beat
    Untch, Michael
    BREAST CARE, 2018, 13 (06) : 453 - 455
  • [43] Is there a role for immunotherapy in HER2-positive breast cancer?
    Esther Holgado
    Jose Perez-Garcia
    Maria Gion
    Javier Cortes
    npj Breast Cancer, 4
  • [44] Treatment strategy for HER2-positive breast cancer
    Mukai, Hirofumi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (04) : 335 - 340
  • [45] Expert Discussion: HER2-Positive Breast Cancer
    Foukakis, Theodoros
    Matikas, Alexios
    Oikonomidou, Olga
    Andreopoulou, Eleni
    Mavroudis, Dimitris
    BREAST CARE, 2021, 16 (04) : 422 - 428
  • [46] Updates in HER2-Positive Metastatic Breast Cancer
    Gadi, V. K.
    Iyengar, Neil
    Isaacs, Claudine
    Kaklamani, Virginia
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 588 - 591
  • [47] Neratinib in HER2-Positive Breast Cancer Patients
    Paranjpe, Rutugandha
    Basatneh, Dima
    Tao, Gabriel
    De Angelis, Carmine
    Noormohammed, Sobia
    Ekinci, Ekim
    Abughosh, Susan
    Ghose, Romi
    Trivedi, Meghana V.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (06) : 612 - 620
  • [48] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [49] Cardiotoxicity in HER2-positive breast cancer patients
    Diana Gonciar
    Lucian Mocan
    Alexandru Zlibut
    Teodora Mocan
    Lucia Agoston-Coldea
    Heart Failure Reviews, 2021, 26 : 919 - 935
  • [50] Frontiers in HER2-positive breast cancer in 2020
    Peddi, Parvin F.
    Slamon, Dennis J.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2021, 33 (01) : 48 - 52